Your session is about to expire
← Back to Search
Ide-cel (bb2121) for Multiple Myeloma
Study Summary
This trial will test if a certain type of T-cell is more effective than another in preventing cancer relapse in patients with multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have MM, treated with 4+ lines including IMID, PI, CD38 antibody, had allo HCT, and show minimal disease post 3 months of HCT.Your liver and heart function tests must be within a certain range, and you need to commit to regular study visits and follow-up for 15 years.I agree to use protection during sex and not donate sperm for 1 year after my treatment.Before starting LD chemotherapy, females who could become pregnant must have a negative pregnancy test and meet certain blood test values. They must also have good liver and kidney function, and cannot have certain medical conditions or be taking specific medications. If someone does not meet these criteria, they may still be able to start LD chemotherapy with the approval of the study's main doctor.I am not pregnant, can follow strict birth control methods for a year, and won't breastfeed.I do not have a fever, infection, need extra oxygen, uncontrolled heart issues, severe blood pressure problems, or worsening organ function.I have myeloma, treated with 4+ therapies including IMID, PI, CD38 antibody, and had a recent autoHCT.You had certain medical procedures or conditions within a specific time frame, have certain medical conditions, are taking certain medications, or have certain infections, which would prevent you from taking part in the study.You have certain levels of abnormal proteins in your blood or urine, or specific findings on imaging or bone marrow tests.
- Group 1: Cohort 1
- Group 2: Cohort 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many test subjects are taking part in this experiment?
"That is right, the information available on clinicaltrials.gov shows that this research is actively seeking volunteers. The listing was published on May 20th, 2022 and updated most recently on July 6th, 2022. So far, only 30 of the required participants have been recruited from a single site."
Are patients able to sign up for this experimental treatment at this time?
"That is accurate. The clinicaltrials.gov website has the latest information on this trial, which was created on 5/20/2022 and updated most recently on 7/6/2022. They are looking for 30 individuals total from 1 location."
What are the risks someone might face by taking Ide-cel (bb2121)?
"Ide-cel (bb2121) is still being clinically tested for both safety and efficacy. However, there is already some data supporting its safety, which gives it a score of 2."
Share this study with friends
Copy Link
Messenger